Adrien Costantini

637 total citations
25 papers, 402 citations indexed

About

Adrien Costantini is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Adrien Costantini has authored 25 papers receiving a total of 402 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 5 papers in Molecular Biology. Recurrent topics in Adrien Costantini's work include Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Adrien Costantini is often cited by papers focused on Cancer Immunotherapy and Biomarkers (15 papers), Lung Cancer Treatments and Mutations (10 papers) and Lung Cancer Diagnosis and Treatment (6 papers). Adrien Costantini collaborates with scholars based in France, United States and Belgium. Adrien Costantini's co-authors include Etienne Giroux‐Leprieur, Jean‐François Emile, Thierry Chinet, Coraline Duménil, Vivianne W. Ding, Biao He, Catherine Julié, Violaine Giraud, Jennifer Dumoulin and Sylvie Labrune and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Adrien Costantini

23 papers receiving 397 citations

Peers

Countries citing papers authored by Adrien Costantini

Since Specialization

Citations

This map shows the geographic impact of Adrien Costantini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adrien Costantini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adrien Costantini more than expected).

Fields of papers citing papers by Adrien Costantini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adrien Costantini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adrien Costantini. The network helps show where Adrien Costantini may publish in the future.

Co-authorship network of co-authors of Adrien Costantini

This figure shows the co-authorship network connecting the top 25 collaborators of Adrien Costantini. A scholar is included among the top collaborators of Adrien Costantini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adrien Costantini. Adrien Costantini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Soluble PD-L1 (sPD-L1) as a biomarker of durable response and survival in patients with advanced non-small cell lung cancer (NSCLC) treated with first-line immune checkpoint inhibitors (ICIs) 2025 ·Cancer Immunology Immunotherapy ·Adrien Costantini, Paul Takam Kamga, Elvire Pons‐Tostivint, Delphine Fradin, (unknown), Etienne Giroux‐Leprieur	0
2	IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer 2025 ·Molecular Cancer ·Kishu Ranjan, Barani Kumar Rajendran, (unknown), Adrien Costantini, (unknown), Shruti Desai, (unknown), Nicole Gianino, Soldano Ferrone, Kurt A. Schalper	2
3	Role of the HGF/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer 2025 ·Cancer Immunology Immunotherapy ·(unknown), Paul Takam Kamga, Catherine Julié, Claude Capron, Adrien Costantini, Coraline Duménil, Jennifer Dumoulin, Violaine Giraud, Florence Parent, Andrei Seferian, Catherine Guettier, (unknown), Élisabeth Longchampt, (unknown), Etienne Giroux‐Leprieur	1
4	Colony stimulating factor-1 (CSF-1) signalling is predictive of response to immune checkpoint inhibitors in advanced non-small cell lung cancer 2023 ·Lung Cancer ·Paul Takam Kamga, (unknown), (unknown), Adrien Costantini, Catherine Julié, Claude Capron, Florence Parent, Andrei Seferian, Catherine Guettier, Jean‐François Emile, Etienne Giroux‐Leprieur	6
5	Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer. 2023 ·Journal of Clinical Oncology ·Adrien Costantini, Kishu Ranjan, Soldano Ferrone, Kurt A. Schalper	1
6	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab 2022 ·Cancer Immunology Immunotherapy ·(unknown), Paul Takam Kamga, (unknown), Adrien Costantini, Catherine Julié, Coraline Duménil, Jennifer Dumoulin, (unknown), Violaine Giraud, C. Dujon, R. Azarian, (unknown), Jean‐François Emile, Etienne Giroux‐Leprieur	4
7	Acute generalized exanthematous pustulosis caused by gemcitabine after nivolumab in metastatic lung adenocarcinoma followed by a dramatic tumor response: A case report 2022 ·Thoracic Cancer ·(unknown), Adrien Costantini, (unknown), Etienne Giroux‐Leprieur	3
8	High Circulating Sonic Hedgehog Protein Is Associated With Poor Outcome in EGFR-Mutated Advanced NSCLC Treated With Tyrosine Kinase Inhibitors 2021 ·Frontiers in Oncology ·Paul Takam Kamga, Aurélie Swalduz, Adrien Costantini, Catherine Julié, (unknown), M. Pérol, Virginie Avrillon, Sandra Ortiz‐Cuaran, Pierre Saintigny, Etienne Giroux‐Leprieur	3
9	Associations of aspirin, statins and metformin with lung cancer risk and related mortality 2021 ·Breathe ·Armin Frille, Adrien Costantini, Katherina Bernadette Sreter	2
10	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer 2021 ·Cancers ·(unknown), Paul Takam Kamga, Adrien Costantini, Catherine Julié, Coraline Duménil, Jennifer Dumoulin, (unknown), Violaine Giraud, Thierry Chinet, Jean‐François Emile, Etienne Giroux‐Leprieur	16
11	Effect of Ruxolitinib on Lung Function after Allogeneic Stem Cell Transplantation 2020 ·Biology of Blood and Marrow Transplantation ·Louise Bondeelle, Sylvie Chevret, Charlotte Hurabielle, (unknown), (unknown), Adrien Costantini, Flore Sicre de Fontbrune, David Michonneau, Gèrard Socié, Abdellatif Tazi, Jean‐David Bouaziz, Anne Bergeron	5
12	ERS International Congress, Madrid, 2019: highlights from the Thoracic Oncology Assembly 2020 ·ERJ Open Research ·Adrien Costantini, Clementine Bostantzoglou, Torsten Blum	3
13	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors 2020 ·Cancers ·Adrien Costantini, Paul Takam Kamga, Catherine Julié, (unknown), Coraline Duménil, Jennifer Dumoulin, (unknown), Violaine Giraud, Thierry Chinet, Martin Rottman, Jean‐François Emile, Etienne Giroux‐Leprieur	10
14	Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients 2019 ·PLoS ONE ·(unknown), Adrien Costantini, Coraline Duménil, Jennifer Dumoulin, (unknown), Violaine Giraud, Sylvie Labrune, Jean‐François Emile, Jean‐Claude Alvarez, Thierry Chinet, Etienne Giroux‐Leprieur	1
15	The electronic nose: emerging biomarkers in lung cancer diagnostics 2019 ·Breathe ·Wouter H. van Geffen, Kevin Lamote, Adrien Costantini, Lizza Hendriks, Najib M. Rahman, Torsten Blum, Jan P. van Meerbeeck	16
16	Nivolumab-refractory patients with advanced non-small-cell lung cancer 2019 ·Lung Cancer ·Adrien Costantini, Vincent Fallet, Jennifer Corny, S. Friard, C. Chouaïd, Boris Duchemann, Etienne Giroux‐Leprieur, Laurent Taillade, Ludovic Doucet, Solenn Brosseau, Marie Wislez, Jean Trédaniel, Jacques Cadranel	15
17	Efficacy of next treatment received after nivolumab progression in patients with advanced nonsmall cell lung cancer 2018 ·ERJ Open Research ·Adrien Costantini, Jennifer Corny, Vincent Fallet, Sophie Renet, S. Friard, C. Chouaïd, Boris Duchemann, Etienne Giroux‐Leprieur, Laurent Taillade, Ludovic Doucet, (unknown), Stéphane Jouveshomme, Marie Wislez, Jean Trédaniel, Jacques Cadranel	22
18	Early metabolic response to chemoradiotherapy by interim FDG PET/CT is associated with better overall survival and histological response in esophageal cancers 2018 ·Digestive and Liver Disease ·Nassim Hammoudi, Christophe Hennequin, Laëtitia Vercellino, Adrien Costantini, Araceli Valverde, Pierre Cattan, L. Quéro	4
19	Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab 2018 ·OncoImmunology ·Adrien Costantini, Catherine Julié, Coraline Duménil, Zofia Hélias‐Rodzewicz, Julie Tisserand, Jennifer Dumoulin, Violaine Giraud, Sylvie Labrune, Thierry Chinet, Jean‐François Emile, Etienne Giroux‐Leprieur	142
20	Immunotherapy: a new standard of care in thoracic malignancies? 2018 ·European Respiratory Journal ·Adrien Costantini, (unknown), Francesca Lucibello, Jorge Moisés, Franck Pagès, Ming‐Sound Tsao, Frances A. Shepherd, Hasna Bouchaab, Marina Chiara Garassino, Joachim G.J.V. Aerts, Julien Mazières, Michele Mondini, Thierry Berghmans, Anne‐Pascale Meert, J. Cadranel	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact